About ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2
ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2 (BST1) is a protein
from Homo sapiens identified by UniProt accession
Q10588, 318 residues long.
MolForge cross-references it against 0 known binders and
184 disease associations.
Target properties
| Protein name | ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2 |
| UniProt accession | Q10588 |
| Gene | BST1 |
| Organism | Homo sapiens |
| Length | 318 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (184)
Diseases linked to this target (Open Targets).
- Parkinson disease · score 0.48
- ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2 measurement · score 0.42
- mean corpuscular hemoglobin concentration · score 0.35
- cerebrospinal fluid biomarker measurement · score 0.33
- blood protein measurement · score 0.31
- protein measurement · score 0.30
- neuroinflammatory disorder · score 0.29
- mean corpuscular volume · score 0.29
- mean reticulocyte volume · score 0.22
- mean corpuscular hemoglobin · score 0.21
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q10588-F1 | alphafold | PREDICTED | 89.66 | — |
Amino-acid sequence (318 residues)
MAAQGCAASR LLQLLLQLLL LLLLLAAGGA RARWRGEGTS AHLRDIFLGR CAEYRALLSP EQRNKNCTAI WEAFKVALDK DPCSVLPSDY DLFINLSRHS IPRDKSLFWE NSHLLVNSFA DNTRRFMPLS DVLYGRVADF LSWCRQKNDS GLDYQSCPTS EDCENNPVDS FWKRASIQYS KDSSGVIHVM LNGSEPTGAY PIKGFFADYE IPNLQKEKIT RIEIWVMHEI GGPNVESCGE GSMKVLEKRL KDMGFQYSCI NDYRPVKLLQ CVDHSTHPDC ALKSAAAATQ RKAPSLYTEQ RAGLIIPLFL VLASRTQL
Explore ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets